Letter from the Commissioner's office at the US FDA
Gespeichert in:
| Veröffentlicht in: | PharmacoEconomics 2007, Vol.25 (1), p.1-2 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | PharmacoEconomics |
| container_volume | 25 |
| creator | Vernon, John A |
| description | |
| doi_str_mv | 10.2165/00019053-200725010-00001 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68379736</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200845398</galeid><sourcerecordid>A200845398</sourcerecordid><originalsourceid>FETCH-LOGICAL-g254t-7c7d799aa03f8333db29f6180b9a63a95cffcf9a3a29f8d398102f9b5d13ecf93</originalsourceid><addsrcrecordid>eNptUdtKAzEQDaLYWv0FWRD0aWsu3c3msVSrQsEH7XPIZpNutNtdk1Tp3zu9KAgSJjOcOXOYC0IJwUNK8uwWY0wEzlhKMeY0wwSneIsdoT4hXABM-fEuxinPBe6hsxDegJEzTk9Rj3AiKCGsj9jMxGh8Yn3bJLE2yaRtGheCa1fG34SktdZpk6i4S85fkund-BydWLUM5uLgB2g-vX-dPKaz54enyXiWLmg2iinXvOJCKIWZLRhjVUmFzUmBS6FypkSmrdVWKKYALyomCoKpFWVWEWYgwQboeq_b-fZjbUKU0Jk2y6VamXYdZF4wLjjLgXi1Jy7U0ki3sm30Sm_JcgwbKkYZiANr-A8LXmUap2Fe6wD_UzDdF3jTGS077xrlN_Lrve5qAwXyU0LvGXybbQCnAOfACFi381TWsQGhy8Mg67Ix1a_SzxnYNxCfh24</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68379736</pqid></control><display><type>article</type><title>Letter from the Commissioner's office at the US FDA</title><source>MEDLINE</source><source>RePEc</source><source>Springer Nature - Complete Springer Journals</source><creator>Vernon, John A</creator><creatorcontrib>Vernon, John A</creatorcontrib><identifier>ISSN: 1170-7690</identifier><identifier>EISSN: 1179-2027</identifier><identifier>DOI: 10.2165/00019053-200725010-00001</identifier><identifier>PMID: 17192113</identifier><language>eng</language><publisher>New Zealand: Springer Healthcare | Adis</publisher><subject>Drug Approval - economics ; Drug Approval - legislation & jurisprudence ; Economic-implications ; Food-and-Drug-Administration ; Government Regulation ; Health technology assessment ; Legislation, Drug ; United States ; United States Food and Drug Administration</subject><ispartof>PharmacoEconomics, 2007, Vol.25 (1), p.1-2</ispartof><rights>COPYRIGHT 2007 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3994,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17192113$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://econpapers.repec.org/article/wkhphecon/v_3a25_3ay_3a2007_3ai_3a1_3ap_3a1-2.htm$$DView record in RePEc$$Hfree_for_read</backlink></links><search><creatorcontrib>Vernon, John A</creatorcontrib><title>Letter from the Commissioner's office at the US FDA</title><title>PharmacoEconomics</title><addtitle>Pharmacoeconomics</addtitle><subject>Drug Approval - economics</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Economic-implications</subject><subject>Food-and-Drug-Administration</subject><subject>Government Regulation</subject><subject>Health technology assessment</subject><subject>Legislation, Drug</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1170-7690</issn><issn>1179-2027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>X2L</sourceid><recordid>eNptUdtKAzEQDaLYWv0FWRD0aWsu3c3msVSrQsEH7XPIZpNutNtdk1Tp3zu9KAgSJjOcOXOYC0IJwUNK8uwWY0wEzlhKMeY0wwSneIsdoT4hXABM-fEuxinPBe6hsxDegJEzTk9Rj3AiKCGsj9jMxGh8Yn3bJLE2yaRtGheCa1fG34SktdZpk6i4S85fkund-BydWLUM5uLgB2g-vX-dPKaz54enyXiWLmg2iinXvOJCKIWZLRhjVUmFzUmBS6FypkSmrdVWKKYALyomCoKpFWVWEWYgwQboeq_b-fZjbUKU0Jk2y6VamXYdZF4wLjjLgXi1Jy7U0ki3sm30Sm_JcgwbKkYZiANr-A8LXmUap2Fe6wD_UzDdF3jTGS077xrlN_Lrve5qAwXyU0LvGXybbQCnAOfACFi381TWsQGhy8Mg67Ix1a_SzxnYNxCfh24</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Vernon, John A</creator><general>Springer Healthcare | Adis</general><general>Springer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>DKI</scope><scope>X2L</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>Letter from the Commissioner's office at the US FDA</title><author>Vernon, John A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g254t-7c7d799aa03f8333db29f6180b9a63a95cffcf9a3a29f8d398102f9b5d13ecf93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Drug Approval - economics</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Economic-implications</topic><topic>Food-and-Drug-Administration</topic><topic>Government Regulation</topic><topic>Health technology assessment</topic><topic>Legislation, Drug</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vernon, John A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>RePEc IDEAS</collection><collection>RePEc</collection><collection>MEDLINE - Academic</collection><jtitle>PharmacoEconomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vernon, John A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Letter from the Commissioner's office at the US FDA</atitle><jtitle>PharmacoEconomics</jtitle><addtitle>Pharmacoeconomics</addtitle><date>2007</date><risdate>2007</risdate><volume>25</volume><issue>1</issue><spage>1</spage><epage>2</epage><pages>1-2</pages><issn>1170-7690</issn><eissn>1179-2027</eissn><cop>New Zealand</cop><pub>Springer Healthcare | Adis</pub><pmid>17192113</pmid><doi>10.2165/00019053-200725010-00001</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1170-7690 |
| ispartof | PharmacoEconomics, 2007, Vol.25 (1), p.1-2 |
| issn | 1170-7690 1179-2027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68379736 |
| source | MEDLINE; RePEc; Springer Nature - Complete Springer Journals |
| subjects | Drug Approval - economics Drug Approval - legislation & jurisprudence Economic-implications Food-and-Drug-Administration Government Regulation Health technology assessment Legislation, Drug United States United States Food and Drug Administration |
| title | Letter from the Commissioner's office at the US FDA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T00%3A19%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Letter%20from%20the%20Commissioner's%20office%20at%20the%20US%20FDA&rft.jtitle=PharmacoEconomics&rft.au=Vernon,%20John%20A&rft.date=2007&rft.volume=25&rft.issue=1&rft.spage=1&rft.epage=2&rft.pages=1-2&rft.issn=1170-7690&rft.eissn=1179-2027&rft_id=info:doi/10.2165/00019053-200725010-00001&rft_dat=%3Cgale_proqu%3EA200845398%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68379736&rft_id=info:pmid/17192113&rft_galeid=A200845398&rfr_iscdi=true |